Bridion

Schering-Plough has launched Bridion (sugammadex) for the reversal of neuromuscular blockade induced by rocuronium or vecuronium.

Sugammadex is a modified gamma cyclodextrin, a selective relaxant binding agent. It forms a complex with the neuromuscular blocking agents rocuronium or vecuronium in plasma reducing the amount of neuromuscular blocking agent available to bind to nicotinic receptors in the neuromuscular junction. This results in the reversal of neuromuscular blockade induced by rocuronium or vecuronium.

Sugammadex should only be administered by, or under the supervision of, an anaesthetist.

View Bridion drug record

Further information: Schering-Plough

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in